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INTRODUCTION
α-Synuclein is a neuronal protein of 140 amino acids, localized to presynaptic terminals. Although the protein is expressed widely throughout the nervous system, it is far from ubiquitous in presynaptic terminals (Maroteaux et al., 1988; Solano et al., 2000; Braak et al., 2000; Li et al., 2002; Phillips et al., 2008; Sharrad et al., 2012a) , but its selective expression and functional significance have not been examined in detail. α-Synuclein functions as a chaperone in the synaptic vesicle cycle for the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein synaptobrevin-2 (Burre et al., 2010) . During neurotransmitter release, the vesicle-SNARE synaptobrevin-2 and the transmembrane-SNAREs syntaxin and synaptosome-associated protein of 25 kDa (SNAP-25) assemble into SNARE complexes between the vesicle and the presynaptic membrane to facilitate exocytosis of neurotransmitter (Sudhof, 2004; Jahn and Scheller, 2006; Sudhof and Rothman, 2009 ). Together, α-Synuclein and cysteine string protein-a (CSPa) chaperone and maintain the levels of synaptobrevin-2 and SNAP-25, respectively, in presynaptic terminals (Burre et al., 2010; Sharma et al., 2011a,b) . Loss of the chaperone activity of α-Synuclein or CSPa exacerbates misfolding and depletion of synaptobrevin-2 or SNAP-25, respectively, from presynaptic terminals. In turn, this leads to a deficit in SNARE-complex assembly and neurodegeneration (Fernandez-Chacon et al., 2004; Chandra et al., 2005; Schmitz et al., 2006; Burre et al., 2010; Greten-Harrison et al., 2010; Sharma et al., 2011a,b) . If the chaperone activity of these two proteins is perturbed, presynaptic terminals that turn over synaptic vesicles at high rates become particularly susceptible to deleterious events associated with neurotransmitter release (Schmitz et al., 2006; Burre et al., 2010; Sharma et al., 2011b) . These observations may be relevant to neurodegenerative diseases that implicate these chaperone proteins (Spillantini and Goedert, 2000; Noskova et al., 2011) , because evidence points toward presynaptic terminals as being the earliest sites disturbed (Wishart et al., 2006; Kramer and Schulz-Schaeffer, 2007; Scheff et al., 2007; Gray et al., 2009; Milnerwood and Raymond, 2010; Schulz-Schaeffer, 2010; Waites and Garner, 2011 ).
Parkinson's disease (PD) is associated with the widespread loss of select classes of neurons and their connections throughout the nervous system. The specific hallmark pathology of sporadic PD is the presence of Lewy bodies and neurites: these comprise abnormal protein aggregates in cell bodies and axons at sites of neurodegeneration (Jellinger, 1986) . The major constituent of Lewy pathology is thought to be aggregated α-Synuclein, suggesting that the protein is involved in the disease pathogenesis (Spillantini et al., 1997) . In support of this notion, three mutations in SNCA, the gene encoding asynuclein (A53T, A30P, and E46K; Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et al., 2004) , as well as gene duplications and triplications (Singleton et al., 2003; Nishioka et al., 2006) , can cause PD. Additionally, genome-wide association studies have identified SNCA as the gene most broadly relevant to sporadic PD (Satake et al., 2009; SimonSanchez et al., 2009 ).
Although PD is best known as a disease involving the central nervous system, the peripheral nervous system, including the enteric nervous system, is also consistently affected (Wakabayashi and Takahashi, 1997; Beach et al., 2009) . Frequently, Lewy pathology is identified in the distal gut of patients diagnosed with PD but is absent from the distal gut of age-matched controls (Wakabayashi et al., 1988; Lebouvier et al., 2010) . We recently reported selective expression of α-Synuclein in the axons of cholinergic enteric neurons in the guinea pig and human distal bowel (Sharrad et al., 2012a) . It is well documented that α-Synuclein expression varies throughout the central nervous system (Solano et al., 2000) , but whether its expression differs between regions of gut is not known. Given that α-Synuclein functions in the synaptic vesicle cycle, it is possibly associated with expression of particular synaptic proteins; however, this has not yet been directly investigated.
This study quantifies the coexistence of α-Synuclein with other synaptic proteins in axons of enteric neuronal populations in the guinea pig ileum. As previously reported for guinea pig rectum, expression of α-Synuclein was closely related to expression of the cholinergic marker vesicular acetylcholine transporter (VAChT) in enteric axons. This study shows that α-Synuclein and VAChT coexpression was also associated with expression of the synaptic vesicle proteins, synaptobrevin-2, synaptophysin, and synaptotagmin-1 and the SNAP-25 chaperone, CSPa, in axons. We speculate that selective expression of α-Synuclein in classes of cholinergic enteric neurons could be related to their high rate of synaptic vesicle turnover and predispose them to degeneration in PD.
MATERIALS AND METHODS

Guinea pig tissue collection and processing for immunohistochemistry
Adult guinea-pigs of either sex (weight 230-360 g) were stunned and killed by exsanguination, in a manner approved by the Animal Welfare Committee of Flinders University, South Australia. Animals were opened along the ventral midline, and the ileum was removed, intestinal contents were flushed, and the preparation was placed in Krebs solution (118 mM NaCl, 4.75 mM KCl, 1.0 mM NaH2PO4, 25 mM NaHCO3, 1.2 mM MgSO4, 11.1 mM Dglucose, 2.5 mM CaCl2). Segments of ileum were pinned in a Sylgard-lined petri dish (Dow Corning, Midland, MI) filled with phosphate-buffered saline (PBS; 0.15 M NaCl, 0.01 M NaH2PO4, pH 7.2), opened longitudinally along the mesenteric border, and stretched. The wholemount was immersed in modified Zamboni's fixative (2% formaldehyde, 15% saturated picric acid in 0.1 M phosphate buffer, pH 7.0) for approximately 24 hours at 4_C. It was then cleared with three washes of 100% dimethyl sulfoxide (DMSO), and stored in PBS at 4_C. The mucosa, submucosa, and circular muscle layers were removed via sharp dissection, leaving the myenteric plexus and longitudinal muscle intact.
Human brain tissue collection
Fresh human neocortical tissue was obtained from the South Australian Brain Bank. Brains were dissected at autopsy, and half of the brain was immersion fixed for histological analysis and the other half snap frozen in dry ice powder and stored at _70_C for biochemical analysis. Brain tissue was from a 72 year-old male with no clinical history of neurological disorders and no significant neuropathology.
Immunohistochemistry
Preparations of myenteric plexus and longitudinal muscle, or strips of circular muscle, were cut into pieces approximately 5-10 mm square and incubated with antisera against different combinations of markers (Table 1) at room temperature for 2 days. Preparations were then rinsed three times in PBS and incubated with secondary antibodies (Table 2) for 4 hours at room temperature. After a final rinse with PBS, preparations were equilibrated with 50%, 70%, and 100% carbonate-buffered glycerol and mounted in 100% carbonate-buffered glycerol (pH 8.6). All antibodies were diluted in 0.1 M PBS (0.3 M NaCl) containing 0.1% sodium azide. Controls for double labeling were performed by omitting one or more primary antibodies from the procedure and by ensuring that all combinations of primary and secondary antisera were free of cross-reactivity.
Western blot
Fresh human neocortical tissue was homogenized in RIPA buffer (50 mM HEPES, 50 mM NaCl, 0.1% sodium dodecyl sulfate [SDS] , 1% NP-40 nonionic detergent, 2 mM EDTA, 2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 5 lg/ml leupeptin, and 10 lg/ml aprotinin). Twenty micrograms of total protein was loaded and separated in 4-12% SDS-PAGE gel and subsequently transferred to polyvinylidene fluoride (PVDF), blocked with 5% skim milk in Tris-buffered saline (150 mM NaCl, 0.1% Tween 20, 20 mM Tris, pH 7.4), and probed with the primary antisera against synaptobrevin-2 (1:2,000; for details see Table 1 ) overnight at 4_C. This was followed by horseradish peroxidasecoupled secondary antisera (1:10,000) for 1 hour, washing, and placement over 1 ml ECF substrate (Super-Signal; Thermo, Rockford, IL) for 5 minutes, then scanned using the ImageQuant LAS 4000 (GE Healthcare, Waukesha, WI).
Antibody characterization
α-Synuclein. Two polyclonal antibodies against α-Synuclein raised in sheep and rabbit were used. The rabbit polyclonal antibody (Rb2-190303-WS), generated by Dr. Wei-Ping Gai, recognizes a 19-kDA band on Western blots of human cerebral cortex extracts at the molecular weight of α-Synuclein and does not cross-react with b-synuclein. Staining is abolished after incubation with 20 lg/ml of the cognate peptide (Jakes et al., 1994) . Staining with the sheep polyclonal antibody against α-Synuclein, also generated by Dr. Wei-Ping Gai, is abolished by preabsorption with the immunizing antigen and recombinant human α-Synuclein (Gai et al., 1999) . The sheep antiserum gave identical labeling, to the level of single varicosities, when double-labeled with the rabbit antiserum in the present study (n = 4), as reported previously (Sharrad et al., 2012a) .
5-Hydroxytryptamine.
The 5-hydroxytryptamine (5-HT) antibody (Incstar, Hudson, WI; catalog No. 20079; lot No. 108072 ) was a polyclonal antiserum raised in goat against 5-HT conjugated to bovine serum albumin. Staining with this antibody was abolished by incubation of the diluted antibody with 100 lg of 5-HT/BSA conjugate (manufacturer's data sheet).
Calbindin.
The calbindin antibody (SWant, Belinzona, Switzerland; catalog No. CB38; lot No. 5.5 ) was a polyclonal raised in rabbit against recombinant rat calbindin D-28k. It recognizes a single band of approximately 27-28 kDa on Western blots of mouse brain homogenate, corresponding to the protein's molecular weight (manufacturer's data sheet; Ng et al., 1996) . The antibody does not stain the brain of calbindin D-28k knockout mice (manufacturer's data sheet). Staining is abolished by preabsorption with 1 lM recombinant rat calbindin D-28k (Reiche et al., 1999) .
Calretinin.
The calretinin antibody (Rogers; catalog No. Ab-6C), generously provided by Dr. J.H. Rogers of Cambridge University, was a polyclonal raised in rabbit against chick calretinin-b-galactosidase fusion protein, containing putative calcium binding domains III and IV (Rogers, 1989a,b) . The antibody stains a single 29 kDa band in rat cerebellum homogenates on Western blots (Bell et al., 2005) , corresponding to the protein's molecular weight (Rogers, 1989b) .
Calcitonin gene-related peptide.
The calcitonin gene-related peptide (CGRP) antibody (Peninsula, Belmont, CA; catalog No. IHC6006; lot No. 040826-2) was a polyclonal raised in rabbit against rat CGRP (peptide sequence HSCATATCVTHRLAGLLSRSGGVVKNNFVPTNVGSEAF-NH2). It recognized a single band of approximately 14 kDa, corresponding to CGRP's molecular weight, on Western blots of horse ileum homogenates (Russo et al., 2010) . Preabsorption of the diluted antibody with the immunogen abolishes staining in horse spinal cord, dorsal root ganglia, and intestine (Domeneghini et al., 2004) .
Cysteine string protein-a.
The CSPa antibody (CSPa; Synaptic Systems, Goettingen, Germany; catalog No. 154 003) was a polyclonal raised in rabbit against a synthetic peptide of C-terminal rat CSPa (peptide sequence TQLTADSHPSYHTDGFN) coupled to keyhole limpet hemocyanin via an added Cterminal cysteine residue. The antibody recognizes a single band of expected size on Western blots of chick retina and brain (Wahlin et al., 2008) Neuronal nitric oxide synthase. The neuronal nitric oxide synthase (nNOS) antibody (Emson; catalog No. K205), generously provided by Dr. P. Emson, was a polyclonal raised in sheep against recombinant rat brain nNOS. It labels an intense band at 160 kDa (theoretical molecular weight of 160 kDa) and a fainter band at 40 kDA on Western blots of guinea-pig inferior mesenteric ganglion and pelvic ganglia (Olsson et al., 2006) .
Somatostatin.
The somatostatin antibody (SOM; Brown; catalog No. Soma 8) was a monoclonal raised in mice against somatostatin-14 conjugated to keyhole limpet hemocyanin using carbodiimide (Buchan et al., 1985) . Preabsorption of the diluted antibody with 100 lg/ml somatostatin-14 abolished labeling in the rat amygdala (Muller et al., 2007) .
Substance P.
The substance P (SP) antibody (Chemicon, Temecula, CA; catalog No. MAB356; lot No. LV1362790) was a monoclonal raised in rats against SP conjugated to bovine serum albumin with carbodiimide (Cuello et al., 1979) . The specificity of the antibody for SP has been validated by radioimmunoassay (Hegarty et al., 2010) . Preabsorption of the antibody with 200 lg/ml of the SP peptide abolishes labeling (Cuello et al., 1979) .
Synaptobrevin-2.
The synaptobrevin-2 antibody was a polyclonal raised in rabbit against human synaptobrevin-2 residues 31-44 (peptide sequence: RRLQQTQAQVDEVV) coupled to keyhole limpet hemocyanin via an added C-terminal cysteine residue. The antibody labels a single band at 17 kDa on Western blots of human brain homogenate (Fig. 1 ).
Synaptophysin.
The synaptophysin antibody (clone SY38; Boehringer, Indianapolis, IN) was a mouse monoclonal raised against presynaptic vesicles from bovine brain. The antibody labels a single band at approximately 38 kDa on Western blots of rat brain lysate, and labeling is abolished after preabsorption of the antibody with extract from purified rat brain presynaptic vesicles (Belichenko et al., 2009 ).
Synaptotagmin-1.
The synaptotagmin-1 antibody (Transduction Labs, Lexington KY; catalog No. S39520) was a mouse monoclonal raised against amino acids 72-223 of rat synaptotagmin-1. The antibody labels a single band at 65 kDa on Western blots of rat brain lysates (manufacturer's data sheet).
Tyrosine hydroxylase.
The tyrosine hydroxylase (TH) antibody (Diasorin, Saluggia, Italy; catalog No. 22941; lot No. 136032 ) was a mouse monoclonal raised against TH extracted from rat PC12 cells. The antibody labels an intense band of 60 kDa (theoretical molecular weight of 56 kDa) and a faint band of 52-54 kDa in Western blots of guinea-pig inferior mesenteric ganglion and pelvic ganglia (Olsson et al., 2006) .
Vasoactive intestinal polypeptide.
The vasoactive intestinal polypeptide (VIP) antibody (Chemicon; catalog No. AB1581, lot No. 0611044826) was a polyclonal raised in sheep against synthetic peptide VIP (1-28) coupled to keyhole limpet hemocyanin with glutaraldehyde. Vesicular acetylcholine transporter. The vesicular acetylcholine transporter (VAChT) antibody (Phoenix Pharmaceuticals, Burlingame, CA; catalog No. HV007; lot No. 417149), was a polyclonal raised in goat against the C-terminal of human VAChT (peptide sequence CTRSRSERDVLLDEPPGLYDAVRLRE). Preabsorption of the antibody with 50 lm of the immunogen abolished labeling in the dentate gyrus of monkeys (Shamy et al., 2007) .
Microscopy and image analysis and processing
Labeled nerves were examined on an Olympus (Tokyo, Japan) IX71 microscope equipped with epifluorescence and highly discriminating filters (Chroma Technology Co., Battledore, VT). Images were captured using a Roper Scientific (Coolsnap) camera and AnalySIS Imager 5.0 (Olympus-SIS, Mu¨nster, Germany) and saved as TIFF files. Matched micrographs of immunohistochemically labeled nerve structures were captured using a _40 objective water-immersion lens and displayed in ImageJ (NIH, Bethesda, MD) as a stack. By rapidly switching between matched micrographs, it was possible to determine accurately whether a single, randomly chosen, labeled varicosity contained the other marker (Olsson et al., 2004; Sharrad et al., 2012a) . Varicosities were selected by moving the mouse cursor rapidly to a region of the ganglion that had not yet been sampled and choosing the closest, infocus varicosity, irrespective of size or intensity of labeling. This method will be referred to as the ''cursorselected coordinate'' method (Sharrad et al., 2012a) . Varicosities that were out-of-focus or overlying intensely labeled nerve cell bodies or other structures were excluded. Five or ten varicosities were selected at widely separated sites in each ganglion, and either 20 or 10 stacks were examined, giving total counts of 100 varicosities in each of four guinea pigs. To analyze axons in the muscle layers, a transect line was drawn and the five varicosities closest to the line were quantified from 20 stacks, resulting in total counts of 100 varicosities in each of the four animals. Both methods give results similar to quantification based on confocal microscopy but allow much larger samples (Sharrad et al., 2012a) . Group data are expressed as percentage means (mean number of varicosities from a sample of 100) 6 SEM, with n referring to the number of animals. Figures were generated from gray-scale images adjusted for contrast and brightness in Adobe Photoshop CS5 and were cropped and resized to improve display of varicosities of interest.
Statistical analysis
All statistical analysis was performed in SPSS19 for PC (SPSS, Chicago, IL). One-way ANOVA with Tukey's HSD test was used to compare the means of more than two samples. Differences were considered significant at P < 0.05.
RESULTS
Reliability of α-Synuclein antisera to label varicosities in the enteric nervous system
We first compared the reliability of the two α-Synuclein antisera to label varicosities in the enteric nervous system. Preparations of guinea-pig ileum double-labeled with both antisera to α-Synuclein revealed nearly complete coexistence in varicosities (sheep α-Synuclein./rabbit α-Synuclein.: 100% 6 0.3%, n . 4; rabbit α-Synuclein./ sheep α-Synuclein.: 99% 6 0.4%, n . 4), suggesting that the antisera could be used interchangeably to reveal varicosities containing α-Synuclein.
Coexistence of neuronal markers with asynuclein in varicosities in myenteric ganglia
We quantified the coexistence of α-Synuclein with characterized markers of neuronal populations in myenteric ganglia of guinea-pig ileum (Costa et al., 1996; Fig. 2) . Myenteric ganglia contain axons of enteric interneurons, intrinsic primary afferent neurons, and spinal afferent and sympathetic neurons. The combination of markers accounts for over 95% of nerve cell bodies in the myenteric plexus (Costa et al., 1996) and the axons of extrinsic spinal afferent (Gibbins et al., 1986 ) and sympathetic (Macrae et al., 1986) neurons.
The proportion of varicosities in each neurochemically defined population that contained α-Synuclein varied widely (Table 3) . For example, just 6% 6 1.1% (n . 4) of SP-IR varicosities in myenteric ganglia were α-Synuclein-IR, but 45% 6 4.9% (n . 4) of NOS-IR varicosities were α-Synuclein-IR. Among the 10 neurochemically defined populations of varicosities studied, a significantly greater proportion of VAChT-IR varicosities contained α-Synuclein immunoreactivity (80% 6 1.7%, n . 4) than any of the other populations studied (P < 0.001 in all cases, f . 82.633 and df . 9). We also quantified the coexistence of VAChT and TH immunoreactivity in varicosities in myenteric ganglia: 0% 6 0% (n . 4) of TH-IR varicosities were VAChT-IR.
Coexistence of α-Synuclein with neuronal markers in varicosities in myenteric ganglia
We also quantified the coexistence of α-Synuclein with markers of neuronal populations the other way around. That is, we quantified the proportion of α-Synuclein-IR varicosities that contained markers of neuronal populations. Again, the proportions varied greatly between populations (Table  4) . For example, α-Synuclein-IR varicosities rarely contained CGRP immunoreactivity (2% 6 1%, n . 4), but a moderate proportion contained NOS immunoreactivity (15% 6 2.3%, n . 4). However, a significantly greater proportion of α-Synuclein-IR varicosities contained VAChT immunoreactivity (78% 6 1.3%, n . 4) than any of the other nine markers of neuronal populations studied (P < 0.001 in all cases, f . 272.325, df . 9).
Coexistence of α-Synuclein with neuronal markers in varicosities in deep muscular plexus
The deep muscular plexus contains axons of excitatory and inhibitory motorneurons that originate in the myenteric plexus and innervate the circular muscle layers (Wilson et al., 1987) . The axons of excitatory and inhibitory motorneurons can be distinguished by VAChT immunoreactivity and NOS or VIP immunoreactivity, respectively. In the deep muscular plexus, α-Synuclein was expressed in nearly all axons of excitatory cholinergic motorneurons, labeled by VAChT immunoreactivity, but was almost never expressed in the axons of inhibitory motorneurons, labeled by VIP or NOS immunoreactivity (Fig. 3, Table 5 ). Almost all α-Synuclein-IR varicosities were VAChT-IR; few were VIP-IR or NOS-IR (Table 6 ).
Coexistence of α-Synuclein with neuronal markers in varicosities in tertiary plexus
The tertiary plexus contains axons of excitatory and inhibitory motorneurons that originate in the myenteric plexus and innervate the longitudinal muscle layers. The axons of excitatory and inhibitory motorneurons can be distinguished by VAChT immunoreactivity vs. NOS or VIP immunoreactivity. As was observed in the deep muscular plexus, almost all VAChT-IR varicosities were α-Synuclein-IR (99% 6 0.4%, n . 4), and no VIP-IR varicosities were α-Synuclein-IR (0% 6 0%, n . 4) in the tertiary plexus (Fig. 3) . All α-Synuclein-IR varicosities were VAChT-IR (100% 6 0.3%, n . 4), and few were VIP-IR (1% 6 0.3%, n . 4).
Coexistence of α-Synuclein and VAChT with synaptic proteins in varicosities in myenteric ganglia
The results indicate that α-Synuclein is preferentially localized with VAChT in varicosities in the myenteric plexus, deep muscular plexus, and tertiary plexus of guinea-pig ileum, similar to the guinea-pig rectum. VAChT is a synaptic vesicle membrane transporter that concentrates acetylcholine in vesicles for release as a neurotransmitter. For this reason, we tested whether α-Synuclein might also be preferentially associated with other synaptic proteins. To do this, we quantified the coexistence of asynuclein and VAChT with the synaptic vesicle proteins synaptophysin, synaptotagmin-1, and synaptobrevin-2 and the SNAP-25 chaperone CSPa in varicosities in myenteric ganglia (Fig. 4) .
Labeling of the myenteric plexus with antisera against synaptophysin, synaptotagmin-1, synaptobrevin-2, or CSPa revealed high densities of labeled axonal varicosities, but not nerve cell bodies, within myenteric ganglia and internodal strands. Nearly all varicosities in myenteric ganglia that contained synaptophysin-, synaptotagmin-1, synaptobrevin-2, or CSPa immunoreactivity also contained α-Synuclein immunoreactivity (Table 1) . When we quantified coexistence the other way around, most asynuclein-IR varicosities were found to contain synaptophysin, synaptotagmin-1, synaptobrevin-2, and CSPa (Table 2) . For myenteric ganglia, we observed that most varicosities that contain VAChT or α-Synuclein also contain the other protein (Table 1) . Therefore, VAChT must be present in most varicosities that contain the synaptic proteins investigated, which we confirmed by quantifying the coexistence of VAChT with synaptophysin and synaptotagmin-1 both ways around (synaptotagmin-1./ VAChT.: 99% 6 0.6%; synaptophysin./VAChT.: 90% 6 0.2%; VAChT./synaptotagmin-1.: 96% 6 0.7%; VAChT./synaptophysin.: 98% 6 0.6%, n . 4). Together these results indicate that, in myenteric ganglia, most varicosities that contain VAChT, α-Synuclein, CSPa, synaptotagmin-1, synaptophysin, or synaptobrevin-2 contain this full complement of synaptic proteins.
Coexistence of α-Synuclein and VAChT with synaptic proteins in varicosities in deep muscular plexus
The expression pattern of the synaptic proteins investigated in the myenteric plexus was very similar in the deep muscular plexus. When preparations of circular muscle labeled with various antisera were investigated, localization of immunoreactivity for synaptophysin, synaptotagmin-1, synaptobrevin-2, and CSPa was restricted to bundles of axons of motorneurons, running parallel to the circular muscle layer (Figs. 5, 6 ). As was observed in myenteric ganglia, nearly all synaptophysin-, synaptotagmin-1-, synaptobrevin-2-, and CSPa-IR varicosities contained α-Synuclein (Table 5) . Quantification of α-Synuclein with markers the other way around revealed that most α-Synuclein-IR varicosities also contained synaptophysin-, synaptotagmin-1, synaptobrevin-2, and CSPa immunoreactivity (Table 6 ). Almost all varicosities in deep muscular plexus that contain VAChT or α-Synuclein contain the other protein (Tables 5, 6 ). This indicates that VAChT is present in all the α-Synuclein-IR varicosities that contain the synaptic proteins studied, and all varicosities containing these synaptic proteins also contain VAChT. This was confirmed directly for synaptophysin and synaptotagmin-1 (synaptotagmin-1./VAChT.: 99% 6 0.3%; synaptophysin ./VAChT.: 92% 6 0.9%; VAChT./synaptotagmin-1.: 99% 6 1.2%; VAChT./synaptophysin.: 98% 6 1.2%, n . 4). As was observed in myenteric ganglia, these results indicate that most varicosities in the deep muscular plexus that contain VAChT, α-Synuclein, CSPa, synaptotagmin-1, synaptophysin, or synaptobrevin-2 contain this full complement of synaptic proteins.
DISCUSSION
Enteric neurons in the myenteric plexus are arranged into complete neural circuits that give rise to the stereotyped reflexes and patterned motor behaviors of the gut. This is mediated by numerous neurotransmitters released by myenteric neurons, including small molecules such as acetylcholine, released from small clear synaptic vesicles, as well as peptides such as substance P and somatostatin, released from large dense-core vesicles. Transmitter release of small molecules and peptides from these two distinct vesicle classes is controlled by overlapping, but different, complements of synaptic proteins (Tandon et al., 1998; Morris et al., 2001 Morris et al., , 2002 . These contribute to different release kinetics following arrival of action potentials at presynaptic terminals (Verhage et al., 1991; Bruns and Jahn, 1995; Hokfelt et al., 2000; Harata et al., 2001; Ohnuma et al., 2001; Barg et al., 2002) . In this study, we quantified the coexistence of α-Synuclein, and other synaptic proteins with markers of various neurotransmitter systems in the axons of myenteric neurons. Strikingly, the expression of the chaperones α-Synuclein and CSPa and the synaptic vesicle proteins synaptobrevin-2, synaptophysin, and synaptotagmin-1 was restricted mostly to axons that were immunoreactive for VAChT.
Selective expression of α-Synuclein in the enteric nervous system of the guinea pig ileum As has been previously reported for guinea pig rectum and human colon, α-Synuclein is expressed in most classes of enteric neurons. The exception is inhibitory noncholinergic motorneurons to the longitudinal and circular muscle layers, which nearly always lack α-Synuclein (Sharrad et al., 2012a) . Within each population, α-Synuclein is preferentially localized in varicosities that contained the cholinergic marker VAChT. In the guinea pig rectum, a small proportion of varicosities in SOM-IR or SP-IR populations contained measurable VAChT: these were the same varicosities that contained α-Synuclein (Sharrad et al., 2012a) . Thus, it is likely that varicosities containing α-Synuclein that were labeled by markers other than VAChT in this study also contained VAChT. One exception to this pattern was in TH-IR varicosities, 32% of which contained α-Synuclein in this study of guinea-pig ileum; these varicosities do not contain VAChT immunoreactivity. Interestingly, in the rectum, α-Synuclein was almost entirely absent from TH-IR varicosities (Sharrad et al., 2012a) , indicating that α-Synuclein immunoreactivity varies between sympathetic neurons in celiac and superior mesenteric ganglia that innervate the ileum compared with sympathetic neurons in the inferior mesenteric ganglion and pelvic ganglia that innervate the rectum (Messenger and Furness, 1993; Olsson et al., 2006) . The similar results of this study and our previous study from two distinct regions of gut suggest that selective expression of α-Synuclein in cholinergic neurons in the gut is not region specific.
Discrepancies in the chemical coding of axons and cell bodies of myenteric neurons
Nerve cells in the myenteric plexus of the guinea pig ileum have been divided into discrete functional classes distinguishable by their unique combinations of molecules and enzymes in their cell bodies ('chemical coding'; Costa et al., 1996) . Choline acetyltransferase (ChAT), a cholinergic marker, has been reported to be consistently co-localized with 5-hydroxytryptamine (5-HT) in interneuronal cell bodies (Steele et al., 1991) . Therefore, the axons of these neurons would be expected to contain both 5-HT and VAChT. However, only 34% 6 3% of 5-HTIR varicosities contained α-Synuclein immunoreactivity, but 80% 6 1.7% of VAChT-IR varicosities contained α-Synuclein immunoreactivity. If all 5-HT-IR varicosities contained VAChT immunoreactivity, then closer to 80% of 5-HT-IR varicosities would be expected to contain α-Synuclein immunoreactivity. However, whether the chemical codes that distinguish the cell bodies of different functional classes of neurons also distinguish their axons has only been recently investigated. A recent study from our laboratory indicates that chemical codes that distinguish different classes of nerve cell bodies in the myenteric plexus of the guinea pig ileum often differ from chemical codes of their axons (Sharrad et al., 2012b) . For example, only 29% 6 5% (n . 4) of 5-HT-IR varicosities contain VAChT immunoreactivity (Sharrad et al., 2012b) . This discrepancy in the colocalization of cholinergic markers in cell bodies and axons was also observed for other markers, including calretinin, SP, and SOM. These observations indicate that care must be taken when extrapolating chemical codes established for cell bodies to axons.
Selective expression of synaptic proteins in cholinergic axons that express α-Synuclein α-Synuclein is largely localized to the axons of neurons (Maroteaux et al., 1988) . In presynaptic terminals, it chaperones synaptobrevin-2 and protects it against misfolding and subsequent depletion from presynaptic terminals, which would otherwise result in a deficit in SNARE-complex assembly (Burre et al., 2010) . Although α-Synuclein plays an auxiliary role in the synaptic vesicle cycle, rather than being directly involved in vesicular function, it is particularly important in protecting terminals that turn over synaptic vesicles at high rates (Chandra et al., 2005; GretenHarrison et al., 2010; Burre et al., 2010) . Enteric nerve terminals that express VAChT presumably release acetylcholine, which is a major fast neurotransmitter in the gut (Galligan et al., 2000) . There was a close association between the presence of α-Synuclein and VAChT in these terminals and the expression of the synaptic vesicle proteins synaptobrevin-2, synaptophysin, and synaptotagmin-1. This association held true for both terminals in myenteric ganglia, reflecting transmission from interneurons and intrinsic sensory neurons, and terminals in the deep muscular plexus, which contain axons of motorneurons that transmit to the circular muscle layers. In addition to the three synaptic vesicle proteins, CSPa, the chaperone of SNAP-25, was localized in the majority of these cholinergic terminals, together with α-Synuclein. Thus, CSPa is also likely to be closely associated with cholinergic axons. It should be noted that this discussion is limited to immunohistochemically detectable expression of proteins. We cannot rule out the possibility that nonimmunoreactive varicosities may express the investigated proteins at levels below the threshold for immunohistochemical detection.
Functional implications of selective expression of α-Synuclein and synaptic proteins in cholinergic axons
The selective expression of α-Synuclein, CSPa, synaptobrevin-2, synaptophysin, and synaptotagmin-1 in particular classes of axons in the enteric nervous system may have functional implications. Most peptidergic varicosities in myenteric ganglia of the guinea pig ileum do not contain VAChT immunoreactivity (Sharrad et al., 2012b) ; a similar finding pertains to the rectum (Sharrad et al., 2012a) . In turn, this suggests that large numbers of peptidergic varicosities lack synaptobrevin-2, synaptotagmin-1, synaptophysin, and CSPa and do not require these proteins for normal synaptic function. Similarly, it has been previously reported that axons of peptidecontaining spinal afferent neurons that lack vesicular glutamate transporters do not express detectable SNAP-25, synaptophysin, synaptotagmin-1, or synaptobrevin-2 (Morris et al., 2005) . The absence of key synaptic proteins from peptidergic axons has also been reported for autonomic ganglia (Gibbins et al., 2003) and glutamatergic ribbon synapses of the retina (Catsicas et al., 1992; Mandell et al., 1992; Brandstatter et al., 1996; Von Kriegstein et al., 1999) . Despite the absence of these synaptic proteins, studies have shown functional transmission from peptidergic axons at neuroeffector junctions (Morris et al., 2001 (Morris et al., , 2002 and from glutamatergic ribbon synapses of inner hair cells (Nouvian et al., 2011) . The mechanisms and the proteins involved in this alternative release pathway have yet to be fully described.
Synaptophysin regulates the readily releasable pool of synaptic vesicles, as well as synapse formation and plasticity (Janz et al., 1999; Daly et al., 2000; Tarsa and Goda, 2002) . Its apparent absence in peptidergic varicosities lacking VAChT suggests that these functions may not operate in some enteric nerve terminals. Synaptotagmin-1 is the Ca2. sensor responsible for fast Ca2.-triggered exocytosis of synaptic vesicles (Tang et al., 2006) and is required for synchronous release of fast neurotransmitters (Maximov and Sudhof, 2005) . Its absence in noncholinergic peptidergic varicosities suggests that they release neuropeptides asynchronously, using a different Ca2. sensor mechanism. This is in accordance with functional studies showing that neuropeptide release is more closely related to bulk changes in intracellular calcium concentrations, accumulating from multiple action potentials invading the terminal (Verhage et al., 1991; Hokfelt et al., 2000) . The present study also suggests that acetylcholine may be the only neurotransmitter in the enteric nervous system that undergoes Ca2.-triggered synchronous release.
Synaptotagmin-1 permits sustained rounds of vesicular exocytosis via repetitive SNARE-complex assembly and disassembly in presynaptic terminals (Maximov and Sudhof, 2005; Tang et al., 2006) . Activity of this nature is prone to cause misfolding and subsequent removal of both SNAP-25 and synaptobrevin-2 (Burre et al., 2010; Sharma et al., 2011b) . CSPa and α-Synuclein are chaperone proteins that protect SNAP-25 and synaptobrevin-2 (Burre et al., 2010; Sharma et al., 2011b) . We speculate that their association with functional cholinergic terminals in the enteric nervous system has evolved to allow rapid and repetitive synaptic activity, which would otherwise leave them vulnerable to activity-dependent misfolding of SNARE proteins. Presumably, noncholinergic peptidergic terminals are less susceptible to such damage, either because they use a different Ca2. sensor or because of their slower rate of vesicle turnover, and therefore do not require such protective mechanisms. Alternatively, they may utilize similar chaperone systems that have yet to be characterized.
Enteric cholinergic neurons may be particularly vulnerable to neurodegeneration in PD
In PD there is widespread loss of cholinergic neurons throughout the nervous system, including the dorsal motor nucleus of the vagus nerve (Gai et al., 1992) , the pedunculopontine nucleus (Jellinger, 1988) , and the nucleus basalis of Meynert (Nakano and Hirano, 1984) . This indicates that cholinergic neurons may be particularly vulnerable to damage in PD. Although enteric neurons show Lewy pathology in PD (Wakabayashi et al., 1988) , it is not clear whether significant neurodegeneration occurs in the myenteric plexus. Furthermore, whether cholinergic neurons in the myenteric plexus are either targeted or spared by this neurodegenerative disease has not been investigated. The preferential expression of α-Synuclein in cholinergic neurons throughout the gut suggests that they may be susceptible in PD.
In summary, we report that α-Synuclein is selectively expressed in the axons of cholinergic enteric neurons in the guinea-pig ileum. These results are similar to a recent report of selective expression of α-Synuclein in cholinergic enteric neurons in the guinea-pig rectum and human colon. The synaptic vesicle proteins synaptotagmin-1, synaptobrevin-2, and synaptophysin and vesicleassociated protein CSPa are also selectively expressed in the same cholinergic enteric nerve terminals. These observations suggest that selective expression of α-Synuclein may be related to specific mechanisms of neurotransmitter release that require a package of synaptic machinery. Studies of cholinergic neurons in gut tissue may be useful in identifying how α-Synuclein is involved in PD.
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Study concept and design: DFS, W-PG, SJHB; acquisition of data: all guinea pig data were acquired by DFS and all human data were acquired by W-PG; analysis and interpretation of data: DFS, W-PG, SJHB; drafting of the manuscript: DFS, W-PG, SJHB; statistical analysis: DFS. Figure 1 . Western blot analysis of synaptobrevin-2. Extracrs (20 μg) of protein from human neocortical tissue were transferred to poly-vinylidene fluoride membranes and probed with antiserum against synaptobrevin-2 (1:2,000; for details see Table 1 ). A single major band of approximately 17 kDa was present (theoretical molecular weight 18 kDa). . Paired fluorescence images of guinea pig ileum myenteric ganglia double labeled with antisera against a-synuclein and either cysteine string protein-a (E,F) or synaptobrevin-2 (G,H) or VAChT and either synaptotagmin-1 (C,D) or synaptophysin (A,B). Varicosities that contained immunoreactivity for both markers are indicated by arrows. a-Syn, a-synuclein; CSPa, cysteine string protein-a; Synbrev-2, synaptobrevin-2; Synphys, synaptophysin; Syntag-1, synaptotagmin-1, VAChT, vesicular acetylcholine transporter. Scale bars = 20μm Figure 5 . Paired fluorescence images of varicose axons in the deep muscular plexus of the guinea pig ileum immunohistochemically double labeled with antisera against VAChT and synaptophysin (C,D), synaptotagmin-1 (G,H), or a-synuclein and either synaptophysin (A,B) or synaptotagmin-1 (E,F). Varicosities that contained immunoreactivity for both markers are indicated by arrows. a-Syn, a-synuclein; Synphys, synaptophysin; Syntag-1, synaptotagmin-1; VAChT, vesicular acetylcholine transporter. Scale bars = 20μm Figure 6 . Paired fluorescence images of varicose axons in the deep muscular plexus of the guinea pig ileum immunohistochemically double labeled with antisera against a-synuclein and either cysteine string protein-a (A,B) or synaptobrevin-2 (C,D). Varicosities that contained immunoreactivity for both markers are indicated by arrows. a-Syn, a-synuclein; CSPa, cysteine string protein-a; Synbrev-2, synaptobrevin-2. Scale bars = 20μm
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